Search results for "Plasma cell"

showing 10 items of 60 documents

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual…

2015

Background Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells (PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and predictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we verified if these markers could be associated with disease stage/response to therapy despite the role of clinical parameters. Results: significant changes in the expression of markers…

OncologyCD20Prognostic variablemedicine.medical_specialtyPathologyHistologybiologybusiness.industryCD58Cell BiologyPlasma cellmedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureImmunophenotypingInternal medicinemedicinebiology.proteinStage (cooking)businessCytometryMultiple myelomaCytometry Part B: Clinical Cytometry
researchProduct

Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

2015

BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625, 000 adult patients diagnosed in 2000-2007 and followed up to 2008. Survival information was provided by 89 participati…

OncologyCancer registry; Europe; Hodgkin lymphoma; Leukaemia; Lymphoma; Multiple myeloma; Non-Hodgkin lymphoma; Relative survivalCancer Researcheducation.field_of_studymedicine.medical_specialtyMyeloidRelative survivalbusiness.industryPopulationFollicular lymphomaPlasma cell neoplasmmedicine.diseaseLymphomaCancer registrymedicine.anatomical_structureOncologyhemic and lymphatic diseasesInternal medicineImmunologyMedicineeducationbusinessInternational Classification of Diseases for OncologyEuropean Journal of Cancer
researchProduct

Castleman's disease presenting as fever of unknown origin: diagnostic value of fluorodeoxyglucose-positron emission tomography/computed tomography.

2009

Abstract: Castleman's disease is an uncommon lymphoproliferative disorder that can present in both nodal and extranodal sites. The cause is unknown, but a disordered immunoregulation, which results in the excessive proliferation of B lymphocytes and plasma cells in lymphoid organs, plays a central role in the development of the condition. Three distinct histologic types (hyaline vascular, plasma cell, and mixed), and 2 anatomical variants (localized and multicentric) have been described. Clinical presentation generally consists of enlargement of lymph nodes or other tissues, fever, asthenia, weight loss, and other general symptoms, associated with nonspecific blood analysis abnormalities, s…

Pathologymedicine.medical_specialtyFeverDiseasePlasma cellFluorodeoxyglucose F18medicineHumansFever of unknown originHyalinemedicine.diagnostic_testbusiness.industryCastleman diseaseCastleman DiseaseGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureLymphatic systemPositron emission tomographyPositron-Emission TomographyFemaleLymphRadiopharmaceuticalsbusinessTomography X-Ray ComputedThe American journal of the medical sciences
researchProduct

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases

2015

Background Multiparameter flow cytometry (MFC) identification and characterization of plasma cells (PCs) is a useful tool to support diagnosis, prognostication, and monitoring of PC diseases (PCD). Currently, the number of MFC markers suited for the identification of PC remains limited. Moreover, antibody therapies against PC-associated markers further compromise the utility of the most widely used reagents (e.g., CD38). Despite markers other than CD38 and CD138 are recognized as potentially useful PC-identification markers, no study has comparatively evaluated their performance in combination with CD38 and CD138. Here we compared the utility of CD229, CD54, and CD319 for the identification…

Pathologymedicine.medical_specialtyHistologymedicine.diagnostic_testCell BiologyBiologyPlasma cellmedicine.diseaseMinimal residual diseasePathology and Forensic MedicineFlow cytometry03 medical and health sciences0302 clinical medicineImmunophenotypingmedicine.anatomical_structureimmune system diseasesEuroFlowhemic and lymphatic diseases030220 oncology & carcinogenesismedicineBone marrowCytometryMultiple myeloma030215 immunologyCytometry Part B: Clinical Cytometry
researchProduct

Primary cutaneous plasmacytosis in a child. Is this a new entity?

2002

Plasma cell proliferations represent a heterogeneous spectrum of disorders. A 7-year-old Caucasian female had suffered an asymptomatic eruption on the trunk for 4 years. Physical examination revealed a plaque with scattered red-brown papules and nodules. Chemical analysis revealed normal proteinaemia. Histological examination of biopsy specimens showed dense perivascular and periadnexal infiltrate, consisting largely of plasma cells, in the superficial and deep dermis. Immunohistochemical study showed that many cells of the infiltrate were CD20 positive. The plasma cells expressed kappa and lambda light chains. The girl's status (age; absence of hypergammaglobulinaemia, lymphadenopathy and …

Pathologymedicine.medical_specialtySkin NeoplasmsPlasma CellsHepatosplenomegalyDermatologyPlasma cellAsymptomaticRisk AssessmentSeverity of Illness IndexDermisBiopsymedicineHumansChildCD20medicine.diagnostic_testbiologybusiness.industryPlasmacytosisBiopsy Needlemedicine.diseaseImmunohistochemistryInfectious Diseasesmedicine.anatomical_structurebiology.proteinPlasmacytomaFemalemedicine.symptombusinessFollow-Up StudiesPlasmacytomaJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

Primary plasmacytoma of the skin.

1996

Primary plasmacytoma of the skin without evidence of bone marrow plasmacytosis is a rare disorder belonging to the heterogenous spectrum of plasma cell neoplasms. With immunohistochemical techniques, differentiation from benign plasma cell aggregates can be accomplished by demonstrating the monoclonality of tumor cells. We describe a patient in whom a solitary primary cutaneous plasmacytoma developed on the left thigh. Immunohistochemically, plasma cells showed restriction of immunoglobulin lambda-chain expression. Underlying multiple myeloma was excluded by serum protein and immunoglobulin electrophoresis, roentgenographic skeletal survey, and bone marrow biopsy. The tumor responded well t…

Pathologymedicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentDermatologyPlasma cellImmunoglobulin lambda-ChainsBiopsymedicineHumansMultiple myelomaSkinbiologymedicine.diagnostic_testbusiness.industryPlasma cell neoplasmMiddle Agedmedicine.diseaseRadiation therapymedicine.anatomical_structurebiology.proteinPlasmacytomaFemaleBone marrowAntibodybusinessPlasmacytomaJournal of the American Academy of Dermatology
researchProduct

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity

2014

// Lavinia Raimondi 1 , Nicola Amodio 1 , Maria Teresa Di Martino 1 , Emanuela Altomare 1 , Marzia Leotta 1 , Daniele Caracciolo 1 , Annamaria Gulla 1 , Antonino Neri 2 , Simona Taverna 3 , Patrizia D’Aquila 4 , Riccardo Alessandro 3 , Antonio Giordano 5 , Pierosandro Tagliaferri 1 and Pierfrancesco Tassone 1,5 . 1 Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy 2 Department of Medical Sciences University of Milan, Hematology1, IRCCS Policlinico Foundation, Milan, Italy 3 Department of Pathology and Forensic and Medical Biotechnology, Section of Biology and…

Pathologymedicine.medical_specialtyStromal cellAngiogenesisMultiple Myeloma; microRNA AngiogenesisBlotting WesternEnzyme-Linked Immunosorbent AssayMice SCIDIn Vitro TechniquesBiologyReal-Time Polymerase Chain ReactionTransfectionMicemiR-199-5pCell MovementMice Inbred NODSettore BIO/13 - Biologia ApplicataCell Line TumorCell AdhesionmedicineAnimalsHumansHypoxiaCell adhesionProtein kinase BCell ProliferationPlasma cell leukemiaNeovascularization PathologicmicroRNA AngiogenesisMicroRNATransfectionPlasma cell leukemiamedicine.diseaseXenograft Model Antitumor AssaysMolecular medicineCell HypoxiaMicroRNAsmedicine.anatomical_structureOncologyAngiogenesis; Hypoxia; Microenviroment; MicroRNA; miR-199-5p; MiRNA; Multiple myeloma; Plasma cell leukemiaCancer researchFemaleAngiogenesisBone marrowMicroenviromentMiRNAMultiple MyelomaResearch Paper
researchProduct

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

2021

Abstract Introduction In the first weeks of the Covid-19 pandemic when healthcare systems in many areas were overstretched, we documented that hospital mortality in multiple myeloma (MM) patients infected by Sars-Cov-2 was 50% higher than in age matched Covid-19 patients without cancer. In the following months, the pressure on healthcare systems in Spain continued although it did not reach the extreme levels of the first weeks of the pandemic. In this study, we proposed to determine if the severity of Covid-19 outcomes in MM patients has changed over the first year of the pandemic. Patients and methods The Spanish MM Collaborative Group (Pethema-GEM) conducted a survey at national level on …

Pediatricsmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryeducationImmunology652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and EpidemiologicalCell BiologyHematologymedicine.diseaseBiochemistryPandemicMedicinebusinesshealth care economics and organizationsMultiple myelomaBlood
researchProduct

Interstitial cystitis with plasma cell bladder infiltration: case report and literature review.

2010

We report the case of a 76 ys-old woman with overactive bladder syndrome, determined by an histological exam of interstitial cystitis with plasma cell infiltration. To the best of our knowledge, in literature only a similar case has been described. The patient has been treated with corticosteroid therapy allowing a transitory benefit; despite this fact, after side effects have been shown, this therapy has been interrupted leading to the worsening of the previous sintomatology. Therefore the patient has undergone to radical cystectomy with orthotopic ileal neobladder. The phlogistic infiltration of the bladder wall is represented by the plasma cells for over 90% of the whole population. In a…

Plasma CellsCystitis InterstitialHumansFemaleHumanAgedArchivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
researchProduct

Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas

2022

The GC reaction results in the selection of B cells acquiring effector Ig secreting ability by progressing toward plasmablastic differentiation. This transition is associated with exclusion from the GC microenvironment. The aberrant expansion of plasmablastic elements within the GC fringes configures an atypical condition, the biological characteristics of which have not been defined yet. We investigated the in situ immunophenotypical and transcriptional characteristics of a nonclonal germinotropic expansion of plasmablastic elements (GEx) occurring in the tonsil of a young patient. Compared to neighboring GC and perifollicular regions, the GEx showed a distinctive signature featuring key r…

Plasma CellsImmunologyGerminal centerDiffuse large B-cell lymphomaDigital spatial profilingSettore MED/08 - Anatomia PatologicaPlasmablastDiffuse large B-cell lymphoma; Digital spatial profiling; Germinal center; Plasmablastdigital spatial profiling; germinal center; plasmablast; diffuse large b-cell lymphomaMyeloid Differentiation Factor 88Tumor MicroenvironmentHumansSettore MED/05 - Patologia ClinicaImmunology and AllergyLymphoma Large B-Cell DiffuseTranscriptomeCD79 AntigensDiffuse large B-cell lymphoma ⋅ Digital spatial profiling ⋅ Germinal center ⋅ Plasmablast
researchProduct